Acute Pneumonia “The most widespread and fatal of all acute diseases, pneumonia is now Captain of...
-
Upload
lenard-warren -
Category
Documents
-
view
215 -
download
0
Transcript of Acute Pneumonia “The most widespread and fatal of all acute diseases, pneumonia is now Captain of...
Acute Pneumonia
“The most widespread and fatal of all acute diseases, pneumonia is now Captain of the Men of Death.”
The Principals and Practice of Medicine
Sir William Oscar, 1901
Principles and Practice of Infectious Diseases
Principals and Practice of Infectious Diseases
Diagnosis of CAP
• Chest radiograph is the most important diagnostic tool
• Clinical presentation is not diagnostic of an etiology
• Yield of pathogens from Gram stain of expectorated sputum from patients with CAP is only 30%–40%.
Diagnosis Chest Radiograph
Gram Stain’s Role in CAP Diagnosis
CAP Treatment Issues
• Causative pathogen frequently not found
– Treatment predominantly empiric
– Pneumococcal and atypical coverage important
• Increasing antibiotic resistance
– Clinical significance in question
• Use double-coverage for pneumococci?
• If outcomes are similar, which agent do we choose?
CAP: Changing Presentation
• Aging of the population
• Increased number of nursing home beds
• Increased number of AIDS cases
• Increased number of organs transplanted
Clin Infect Dis 2000;31:347-82Ramirez et al. IDSA 2000Clin Infect Dis 2000;31:347-82Ramirez et al. IDSA 2000
16%
6%
1%
10%
7%20%
40%S. pneumoniae
H. influenzae
Legionella spp.
M. pneumoniae
C. pneumoniae
M. catarrhalis
Others
AtypicalAtypicalPathogens:Pathogens:
23%23%
AtypicalAtypicalPathogens:Pathogens:
23%23%
Key Bacterial Pathogens in CAP
• Up to 60% of cases have an unknown etiology• Up to 15% with ≥ 2 etiologies
The reported age-related mortality per 100,000 US population from pneumonia and influenza in individuals >15 yr, 1982-1990
0
200
400
600
800
1000
1200
15-24 25-34 35-44 45-54 55-64 65-74 75-84 85+
AGE
Deatth rates per 100,000
19901982
ASCAP Guidelines for Outpatient Treatment of CAP
• Otherwise healthy patients (all ages)–First-line
• Azithromycin PO
–Alternative first-line• Moxifloxacin PO (preferred) or levofloxacin PO
or clarithromycin PO or gatifloxacin PO
The ASCAP 2002 Consensus Panel. Hosp Med Consensus Rep. 2002:1-32; Emerman CL, Bosker G. In: Bosker G, ed. Textbook of Adult and Pediatric Emergency Medicine. 2nd ed. Atlanta, Ga: American Health Consultants. 2002:375-395.
Indications for Hospitalization
• Pulse >140, SBP <90 mm Hg, and/or respiratory rate >30/min
• Altered mental status
• Hypoxemia (PO <60 mm Hg)
• Suppurative complication
• Metabolic abnormality
ASCAP Guidelines for Inpatient Treatment of CAP
• Hospitalized, non-ICU– First-line
• Ceftriaxone PLUS azithromycin IV– Alternative first-line
• Moxifloxacin or levofloxacin IV or gatifloxacin
• ICU Patients– First-line
• Ceftriaxone IV PLUS levofloxacin IV (±) aminoglycoside or ceftriaxone IV PLUS azithromycin IV (±) an antipseudomonal agent
– Alternative first-line• Ciprofloxacin IV PLUS an aminoglycoside IV PLUS azithromycin
IV The ASCAP 2002 Consensus Panel. Hosp Med Consensus Rep. 2002:1-32; Emerman CL, Bosker G. In: Bosker G, ed. Textbook of Adult and Pediatric Emergency Medicine. 2nd ed. Atlanta, Ga: American Health Consultants. 2002:375-395.
ASCAP Guidelines for Inpatient Treatment of CAP – Special Considerations
• Nursing home acquired– First-line
• Ceftriaxone IV PLUS azithromycin IV – Alternative first-line
• Ceftriaxone PLUS doxycycline or moxifloxacin or levofloxacin IV or gatifloxacin
• Severe, bacteremic CAP with documented Streptococcus pneumoniae*– First-line
• Ceftriaxone PLUS moxifloxacin or ceftriaxone IV PLUS levofloxacin IV
– Alternative first-line• Vancomycin† PLUS azithromycin IV
* Showing high-level or complete resistence to macrolides, cephalosporins and/or penicillin.
† If S. pneumoniae demonstrates complete resistance to extended-spectrum quinolones (very rare), third generation cephalosporins and macrolides, then vancomycin may be required as part of initial therapy, although this would be necessary only in rare circumstances.
The ASCAP 2002 Consensus Panel. Hosp Med Consensus Rep. 2002:1-32; Emerman CL, Bosker G. In: Bosker G, ed. Textbook of Adult and Pediatric Emergency Medicine. 2nd ed. Atlanta, Ga: American Health Consultants. 2002:375-395.
Infections caused by S. pneumoniae, USA 1997
Otitis media 7,000,000
Pneumonia 500,000
Bacteremia 50,000
Meningitis 3,000
Death 40,000
Mortality rate (30-40%) for bacteremic cases
Worldwide Prevalence Rates for Penicillin Resistant S.pneumoniae
Unknown
< 5%
5-10%
10-25%
> 25% Doern CID 1998; Felmingham JAC 1996 and 2000.Zhanel Low and Hoban AAC 1999.
0
5
10
15
20
25
30
35
40
1979-87 1988-89 1990-91 1992-93 1994-95 1997-98 1999-00
Per
cen
t
Resistant (MICs >2)
Intermediate (MICs 0.12-1)
5589 487 524 799 1527 1601 1531 1940 35 15 17 19 30 34 33 45
2001-02
1980’s 1990’s
Penicillin Resistance with S pneumoniae in the United States
Antimicrob Agents and Chemother 2001;45:1721 and submitted
S. pneumoniae Resistance Rates Selected Agents, 1999-2000*
* n=1,531 isolates; 33 U.S. medical centers, winter (1999-2000)
Antimicrobial % Resistance
Macrolides 25.9
Clindamycin 8.8
Tetracycline 16.4
Chloramphenicol 8.6
TMP/SMX 30.3
Fluoroquinolones 1.2
Antimicrob Agents and Chemother 2001;45:1721
Clin Infect Dis 2002;34:330
• PBP alterations - not -lactamaseproduction - mediate penicillin resistance in pneumococcusthus - lactamase inhibitors do not enhance activity of -lactam agents against penicillin-resistant pneumococci
PRSP-Mechanism
Drug-Resistant S. pneumoniae
• Age > 65 years or < 5 years
• Exposure to a child in a day care center
• Multiple medical comorbidities
• Alcoholism
• Recent use of antibiotics
• Immunosuppression
• Recent hospitalization
MIC Interpretive Criteria for S. pneumoniae Susceptibility to Ceftriaxone Effective
January 1, 2002
Meningeal Breakpoints Nonmeningeal Breakpoints
Sensitive 0.5 g/mL 1 g/mL
Intermediate 1 g/mL 2 g/mL
Resistant 2 g/mL 4 g/mL
For cerebrospinal fluid isolates, report only meningitis interpretations.For all other isolates, report interpretations for both meningitis and nonmeningitis.
NCCLS. 2002. M100.
Mortality of Hospitalized Patients With Invasive Pneumococcal Disease
Years N Mortality Reference
Austrian & Gold
Kings County Brooklyn Hospital
1952-62 1130 13%Annals Int Med
1964
Fine
Meta-analysis of 127 cohorts 1966-95 4432 12% JAMA 1996
Feikin
Population-based, active surveillance
1995-97 5837 12%Am J Public
Health 2000
Mortality Due to Pneumococcal Pneumonia / Sepsis
Location YearPatients with
DRSP (%)
Mortality (%)
P StudyPen-S Pen-NS
Ohio 1991-94 39/499 (8) 19 21 NS Plouffe, JAMA 1996
Israel 1987-92 67/293 (23) 11 16 NS Rahav, Medicine 1997
Barcelona 1984-93 145/504 (29) 24 38 NS Pallares, NEJM 1995
South Africa‡ 1993-94 35/108 (32) 16 24 NS Friedland PIDJ 1995
Atlanta 1994 44/192 (23) 11 23 NS Metlay, CID 2000
Barcelona 1996-9849/101-Pen (49)
12/101-Mac (12)
6
14*
16
7†
NS
NSEwig, AJRCCM 1999
N. America 1995-97 741/4193 (18) 11% 14 NS Feikin AJPH 2000
* Mac-S; † Mac-NS‡ Children Bishai, JAC 2001
New NCCLS Breakpoints for Streptococcus pneumoniae
Overall Rates of Resistance (I + R)
Drug Old Breakpoints New Breakpoints
Amoxicillin 24.2% 6.3%
Amoxicillin/clavulanate 24.2% 6.3%
Ceftriaxone/cefotaxime 24.0% 4.0%
Cefuroxime 29.1% 27.3%
Antimicrob Agents Chemother 2001;45:1721-29NCCLS, M100 document January 2002
Antibiotic Activity Against H. influenzae
MIC90 (g/m )LGati Cipro Trova Azithro Clari
. H influenzae-Lac t (-) 1002isolates-Lac t (+) 485isolates
<0.03
<0.03
<0.015
<0.015
<0.03
<0.03
2.0
2.0
16.0
16.0
H. influenzaeIncreasing -Lactamase Production
0%
5%
10%
15%
20%
25%
30%
35%
1970 1984 1988 1992 1996
Slide28
Atypical Pneumonia
• AP encompasses pneumonias due to Mycoplasma pneumoniae, Chlamydia pneumoniae and Legionella spp*
• Prospective studies have failed to identify the cause of 40% to 60% of CAP cases‡
• Today, AP implies–An often benign course (ambulatory)*–Gradual onset§
–Systemic complaints often greater than respiratory complaints§
• AP often a “mixed” infection*
**File TM Jr, et al. File TM Jr, et al. Infect Dis Clin North Am. Infect Dis Clin North Am. 1998;12:572,570,579.1998;12:572,570,579. ††Reimann HO.Reimann HO. JAMA JAMA. 1938;111:2377,2384. . 1938;111:2377,2384. ‡‡Bartlett JG, et al. Bartlett JG, et al. Clin Infect DisClin Infect Dis. 1998;26:813.. 1998;26:813.§§Levison ME. Levison ME. Harrison’s Principles of Internal Medicine. Harrison’s Principles of Internal Medicine. McGraw-Hill; 1998:1439.McGraw-Hill; 1998:1439.
Pharmacokinetics and Pharmacodynamic Parameters
Con
cen
trat
ion
Time (hours)
MIC
0
Peak/MIC
AUC/MIC
Time > MIC
AUC/MIC90 Ratio of Major FQ for S. pneumoniae
Dose Cmax AUC MIC AUC/MICLevoTrovaCiproGati
500mg200mg500mg400mg
5.12.12.44.0
47.926.711.651.0
2.00.252.00.5
24.0106.6
5.8102.0
FQ Prescription per Capita and Frequency of Pneumococci with Reduced
Susceptibility to FQs in Canada According to Patient’s Age (Bars)
Treatment for 7 to 14 days
2 days
2 days
Newly HospitalizedCAP Patients(18 years)
Gatifloxacin IV400 mg QD
n=141
Gatifloxacin PO400 mg QD
Ceftriaxone IV 1 or 2 g (32%) QD ± Erythromycin IV
0.5 or 1 g (39%) q6hn=142
Clarithromycin PO500 mg BID
Fogarty C et al. J Respir Dis. 1999;20(suppl 11):S60-S69.
Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information.
Gatifloxacin vs Ceftriaxone ± Macrolide in Hospitalized CAP Patients
Gatifloxacin vs Ceftriaxone ± Macrolide* in CAP: Clinical and Bacteriologic Response
*Macrolides were erythromycin IV and clarithromycin PO step-down.†No. cured/total of clinically evaluable patients; ‡No. eradicated/total of microbiologically evaluable patients.NSD=not statistically differentFogarty C et al. J Respir Dis. 1999;20(suppl 11):S60-S69.
Gatifloxacin efficacy rates in CAP from clinical trials used as a basis for approval—up to 90%
Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information.
97 97
9092
Gatifloxacin Ceftriaxone ± erythromycin/clarithromycin
Clinical Cure† Microbiologic Eradication‡0
70
80
90
100
96/99 96/106 69/71 73/79
Pat
ien
ts w
ith
Cu
re
or
Era
dic
atio
n (
%)
NSD NSD
*Macrolides were erythromycin IV and clarithromycin PO step-down; †ATS severity scores; ‡No. cured/total of clinically evaluable patients.NSD=not statistically differentNiederman MS et al. Am Rev Respir Dis. 1993;148:1418-1426; Fogarty C et al. J Respir Dis. 1999; 20(suppl 11):S60-S69.
Gatifloxacin efficacy rates in CAP from clinical trials used as a basis for approval—up to 90%
Please see IMPORTANT SAFETY INFORMATION slides. Please see full Prescribing Information.
Gatifloxacin vs Ceftriaxone ± Macrolide* in CAP: Clinical Response by Pneumonia Severity†
Gatifloxacin Ceftriaxone ± erythromycin/clarithromycin
NSD NSD NSD
All Patients Mild/Moderate CAP‡
Pat
ien
ts w
ith
C
ure
(%
)
Severe CAP ‡0
70
80
90
100 97
91
100
9296
90
96/99 96/106 28/28 24/26 68/71 72/80
Role of FQ in Treatment of CAP
• To limit the emergence of FQ-resistant strains, To limit the emergence of FQ-resistant strains, the new FQ should be limited to adults:the new FQ should be limited to adults:
• For whom one of the above regimens has already failed,
• Who are allergic to alternative agents,
OR• Who have documented infection with highly drug-
resistant pneumococci (MIC ≥4 µg/ml)
Pneumococcal Vaccine
• Older than 2 years with:• functional or anatomic asplenia**• immunocompromise or immunosuppression**• HIV infection**• malignancy**• chronic renal failure, HD, nephrotic syndrome**• chronic cardiovascular or pulmonary illness**• Alaskan natives, American Indians
• Revaccination• if >65 years, consider revaccination in 5 yr**
CDC Recommendations: Who Should Receive Influenza Vaccine?
• Persons at increased risk (age 6 mos)
• Hospital and outpatient employees
• Nursing home employees with patient contact
• Home health care providers working with high-risk persons
• Household members of high-risk persons
• Persons desiring to avoid influenza infection
MMWR. 1999;48:5-7.
Guidelines for CAP
Guideline Inpatient Outpatient
IDSA -lactam + macrolide or
Fluoroquinolone
Macrolide or
Doxycycline or
Fluoroquinolone
ATS IV azithromycin or
-lactam + macrolide or
Fluoroquinolone
Macrolide or doxy
-lactam + macrolide
Fluoroquinolone
CDC -lactam + macrolide or
Fluoroquinolone
-lactam or macrolide or doxycycline
(reserve quinolones)
Clin Infect Dis 2000;31:347-82Am J Resp Crit Care Med 2001;163:1730-54Arch Int Med 2000;160:1399-1408
I prefer to decide my prescription strategies for CAP on the basis of severity of the patient’s condition, the presence of comorbidities, and the epidemiologic pattern in each geographical area.
J. Rello - Chest (May 98)
Acknowledgements
• Dr Naiel Nassar MD FACP
Assistant professor of Medicine
UTSW Dallas